

Vertex CF drug candidate shows promising results

Mass High Tech: The Journal of New England Technology

[Vertex Pharmaceuticals](#) [1] (Nasdaq:VRTX) has announced additional positive results for its experimental therapy for Cystic Fibrosis.

A Phase 3 Study of the drug candidate, called VX-770, in children between 6 and 11 with a specific type of CF, found lung function improved by 17.4 percent. This is a 24-week analysis of an ongoing study, which focuses on a sub-set of patients with a certain gene mutation.

[SOURCE](#) [2]

Source URL (retrieved on 01/29/2015 - 3:45am):

http://www.mdtmag.com/news/2011/03/vertex-cf-drug-candidate-shows-promising-results?qt-recent_content=0

Links:

[1] <http://www.masshightech.com/search.html?q=Vertex%20Pharmaceuticals&t=1>

[2] <http://www.masshightech.com/stories/2011/03/28/daily22-Vertex-CF-drug-candidate-shows-promising-results-.html>